Genetic Determinants of Opioids Analgesia

This study has been completed.

First Received: September 12, 2005 Last Updated: October 28, 2008 History of Changes

Sponsored by:	Hadassah Medical Organization
Information provided by:	Hadassah Medical Organization
ClinicalTrials.gov Identifier:	NCT00226564

Purpose

The response to opioids varies greatly among individuals. Some of these variability is accounted for by genetic factors.

The present study was designed to evaluate the possibility that genetic polymorphism in the gene encoding for mu opioid receptor may explain variability in the response to alfentanil during lithotripsy.

Condition	Intervention
Nephrolithiasis	Drug: Alfentanil

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	The Effect of mu Opioid Receptor Polymorphism on the Response to Alfentanil During Lithotripsy

Resource links provided by NLM:

MedlinePlus related topics: Kidney Stones

Drug Information available for: Alfentanil hydrochloride Alfentanil

U.S. FDA Resources

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:

Total alfentanil dose used during the procedure.
The extent of respiratory depression.

Estimated Enrollment:	100
Study Start Date:	August 1997

Eligibility

Ages Eligible for Study:	20 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age > 20

Exclusion Criteria:

Regular use of opioid drugs
Known hypersensitivity to alfentanil

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00226564

Locations

Israel
Hadassah Medical Organization
Jerusalem, Israel

Sponsors and Collaborators

Hadassah Medical Organization

Investigators

Principal Investigator:

Yoseph Caraco, MD

Hadassah Medical Organization, Jerusalem, Israel

More Information

No publications provided

Study ID Numbers:	yc19554-HMO-CTIL
Study First Received:	September 12, 2005
Last Updated:	October 28, 2008
ClinicalTrials.gov Identifier:	NCT00226564 History of Changes
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Study placed in the following topic categories:

Anesthetics, Intravenous
Urolithiasis
Central Nervous System Depressants
Anesthetics
Alfentanil
Narcotics
Urologic Diseases

Anesthetics, General
Kidney Diseases
Analgesics
Peripheral Nervous System Agents
Nephrolithiasis
Analgesics, Opioid

Additional relevant MeSH terms:

Anesthetics, Intravenous
Urolithiasis
Physiological Effects of Drugs
Anesthetics
Central Nervous System Depressants
Alfentanil
Narcotics
Pharmacologic Actions
Urologic Diseases

Anesthetics, General
Sensory System Agents
Therapeutic Uses
Kidney Diseases
Analgesics
Peripheral Nervous System Agents
Nephrolithiasis
Central Nervous System Agents
Analgesics, Opioid

ClinicalTrials.gov processed this record on July 02, 2009